Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder

Next Previous
Search
Trial Profile

A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Gemcitabine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Jun 2023 Updated results of safety and efficacy, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 08 Jun 2021 Results assessing safety and efficacy of pembro added to TMT in muscle-invasive urothelial cancer of the bladder (MIBC) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jan 2021 Planned End Date changed from 1 Dec 2026 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top